LUNG INFLAMMATION
肺部炎症
基本信息
- 批准号:2215286
- 负责人:
- 金额:$ 32.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1979
- 资助国家:美国
- 起止时间:1979-06-01 至 1994-11-30
- 项目状态:已结题
- 来源:
- 关键词:Arthus phenomenon Porifera Shwartzman phenomenon adenosine alternatives to animals in research cell cell interaction cell free system complement complement receptor cytokine endotoxins guanine nucleotide binding protein histochemistry /cytochemistry human tissue immune complex immunopharmacology inflammation leukocyte activation /transformation lung disorder neutrophil nitric oxide radiotracer respiratory pharmacology saltwater environment tissue /cell culture vascular endothelium vasodilators
项目摘要
Neutrophils mediate tissue injury in two classical models of experimental
pathology: the Arthus lesion(1903) and the Shwartzman phenomenon (1927).
The aim of this proposal is to explain in the language of 1989 how
vascular injury induced by immune complexes and complement (the Arthus
lesion) differs from the induced by endotoxin, cytokines and complement
(the Shwartzman phenomenon). We will study neutrophil/endothelial cell
interactions in vitro to test novel hypotheses of "triggering" and
activation" of neutrophils. We will determine the functional effects on
human neutrophils and cytoplasts of "defensive" molecules release from
activated vs. resting endothelial cells. A variety of endothelial cells
(eg HUVEC) will be exposed to endotoxin or cytokines and the release
measured of a) prostacyclin b) adenosine c) endothelium-derived
relaxation factor (EDRF, or NO) and d) sphingosine (an endogenous
inhibitor of O2 generation). The effects of these molecules will be
studied on neutrophils or cytoplasts activated by chemoattractants or
immune complexes with respect to a) heterotypic adherence (to HUVEC), b)
cell-cell aggregation, c) disaggregation d) chemotaxis in several
systems, and e) release of O-2 H2 O2 and lysosomal enzymes. We will also
expose neutrophils activated by chemoattractants and immune complexes to
PGI2 adenosine, NO and sphingosine. Stimulus/response coupling will be
examined with attention to receptors for iC3b and immune complexes
(FcRII,FcRIII), cytosolic pH and free calcium (pH, and Cai) 45Ca fluxes,
membrane viscosity, membrane potential (delta psi), crosslinking of
cytoskeletal proteins, microtubule assembly, phospholipid remodelling,
and protein phosphorylation. We will compare the susceptibility of
resting HUVEC with cells activated by endotoxin or cytokines (IL-1, TNF
and IFN) to killing by neutrophils exposed to chemoattractants (C5a, LTB,
FMLP). We will study whether immune complexes present a) in the bulk
phase b) on the HUVEC monolayer, or c) in the subphase, provoke
neutrophil-mediated cell injury despite release of "defensive" molecules
from HUVEC. Finally, using marine sponge cells and human neutrophils, we
will study whether 20.4 and other cis unsaturated fatty acids activate a
novel GTP-binding protein the function of which is mimicked by
phospatidic acid. These studies will employ novel liposomal methods for
phospholipid presentation. Thus we will be able to define the roles
played by cytokine activated endothelial cells (the Shwartzman model) and
immune complexes (the Arthus model) in neutrophil-mediated blood vessel
injury.
中性粒细胞介导了两个经典模型的实验模型
病理学:Arthus病变(1903)和Shwartzman现象(1927)。
该提议的目的是用1989年的语言解释
免疫复合物和补体引起的血管损伤(Arthus
病变)与诱导的内毒素,细胞因子和补体不同
(Shwartzman现象)。我们将研究中性粒细胞/内皮细胞
体外相互作用以测试“触发”和
激活“中性粒细胞。我们将确定对
“防御”分子的人类嗜中性粒细胞和细胞体从
活化的与静息内皮细胞。多种内皮细胞
(例如HUVEC)将暴露于内毒素或细胞因子和释放
测量A)前列环蛋白b)腺苷c)内皮衍生
松弛因子(EDRF,或NO)和D)鞘氨酸(内源性
O2代的抑制剂)。这些分子的影响将是
在中性粒细胞或细胞体上进行了研究
免疫复合物相对于a)异型依从性(对HUVEC),b)
细胞细胞聚集,c)分类d)在几种
系统,E)O-2 H2 O2和溶酶体酶的释放。我们也会
暴露于化学吸引剂和免疫复合物激活的中性粒细胞
PGI2腺苷,NO和鞘氨醇。刺激/响应耦合将是
对IC3B和免疫复合物的受体的关注进行了检查
(FCRII,FCRIII),胞质pH和游离钙(pH和CAI)45CA通量,
膜粘度,膜电位(Delta PSI),交联
细胞骨架蛋白,微管组件,磷脂重塑,
和蛋白质磷酸化。我们将比较
用内毒素或细胞因子激活的细胞静止HUVEC(IL-1,TNF)
和IFN)被暴露于趋化剂的中性粒细胞杀死(C5A,LTB,
FMLP)。我们将研究免疫复合物是否存在a)
B阶段B)在HUVEC单层上,或C)在子阶段中挑衅
尽管释放了“防御性”分子,但中性粒细胞介导的细胞损伤
来自Huvec。最后,使用海洋海绵细胞和人类嗜中性粒细胞,我们
将研究20.4和其他顺式不饱和脂肪酸是否激活A
新型GTP结合蛋白的功能被模仿
凤凰酸。这些研究将采用新颖的脂质体方法
磷脂表现。因此,我们将能够定义角色
由细胞因子激活的内皮细胞(Shwartzman模型)和
中性粒细胞介导的血管中的免疫复合物(Arthus模型)
受伤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GERALD WEISSMANN其他文献
GERALD WEISSMANN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GERALD WEISSMANN', 18)}}的其他基金
相似海外基金
Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer
免疫调节生物材料可增强 T 细胞对三阴性乳腺癌的反应
- 批准号:
10699815 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
ALTERING THE IMMUNE LANDSCAPE TO AUGMENT BONE REGENERATION
改变免疫景观以增强骨再生
- 批准号:
10727797 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Marine sponge depsipeptides to minimize antibiotic collateral damage
海洋海绵缩酚肽可最大程度地减少抗生素的附带损害
- 批准号:
10726689 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Point-of-Care Diagnosis of Esophageal Cancer in LMICs
中低收入国家食管癌的即时诊断
- 批准号:
10649166 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别:
Gelbrane: Combined Gel and Membrane for Robust Western Blotting
Gelbrane:结合凝胶和膜实现稳健的蛋白质印迹
- 批准号:
10759072 - 财政年份:2023
- 资助金额:
$ 32.19万 - 项目类别: